Research Article
Evaluation of Provider Screening Practices for Fracture Risk Assessment among Patients with HIV Disease
Table 2
Baseline demographics and characteristics.
| | Variable | Adult fragility fracture (n = 14) | No adult fragility fracture (n = 31) | value |
| | Age (years), mean (SD) | 58.7 (12.1) | 51.3 (13.3) | 0.08 | | Male gender, n (%) | 11 (78.6) | 17 (54.8) | 0.19 | | Race/ethnicity, n (%) | 0.36 | | Black | 5 (35.7) | 12 (40) | | White | 8 (57.1) | 10 (33.3) | | Hispanic | 1 (7.1) | 7 (23.3) | | Other | 0 | 1 (3.3) | | Smoking, n (%) | 8 (57.1) | 20 (64.5) | 0.64 | | ETOH abuse, n (%) | 3 (23.1) | 5 (18.5) | 1.0 | | IV drug use, n (%) | 2 (14.3) | 6 (19.4) | 1.0 | | Diabetes history, n (%) | 1 (7.1) | 4 (12.9) | 1.0 | | Hepatitis C coinfection, n (%) | 8 (57.1) | 10 (32.3) | 0.11 | | CD4 nadir, median (IQR) | 472 (375–725) | 449 (311–678) | 0.45 | | Virologic suppression >2 years, n (%) | 11 (78.6) | 21 (72.4) | 1.0 | | Years infected, median (IQR) | 12 (10–18) | 15 (6–26) | 0.62 | | AIDS defined, n (%) | 4 (28.6) | 4 (12.9) | 0.23 | | Months on ART, median (IQR) | 39 (29–77) | 76 (49–90) | 0.05 | | Protease inhibitor exposure, n (%) | 6 (46.2)% | 6 (21.4) | 0.11 | | Tenofovir (DF or AF) exposure, n (%) | 11 (84.6) | 26 (89.7) | 0.64 | | DEXA scan recommended, n (%) | 14 (100) | 21 (67.7) | 0.02 | | FRAX score (major osteoporotic fracture), mean (SD) | 11.2 (5.8) | 5.3 (5.0) | <0.01 | | FRAX score (hip fracture), mean (SD) | 1.9 (1.3) | 0.6 (0.7) | <0.01 |
|
|
